Page 27 - PD-L1 EbookV2 Flip PDF

collaborative study to accelerate the clinical readiness of the test. It is essential to define a
reference method/material, or a unified test or algorithm, so as to provide traceability to a
reproducible assessment of the threshold. Most importantly, generated data cannot be
aggregated to develop guidelines until the results are standardized, and guidelines cannot
be issued and implemented until all the methods are harmonized.

Finally, there is an urgent need for integrative initiatives to support the ongoing
collaborations amongst the different stakeholders, including academic research institutions
and university hospitals, pathologists, physicians, pharmaceutical and diagnostic companies
and key bodies.

References

1. Goldman Sachs (2015) Americas: Healthcare: Pharmaceuticals - Pharma Bus Trip: Takeaways from BMY,
MRK, PFE and ZT (Published 27 February 2015)
https://360.gs.com/research/portal//?st=1&action=action.binary&d=18911921&fn=/document.pdf&a=b7d23
9e796be4d8682ff584ca13328b2 [available when accessed March 2016]

2. The ASCO Post - NRAS Mutations in Advanced Melanoma Correlate With Increased Benefit From
Immunotherapies (Published 3rd March 2015) http://www.ascopost.com/ViewNews.aspx?nid=23616

Originally published at Diaceutics.com, 16 March 2015

Page 27 of 31